How to manage recurrence after radical prostatectomy

Poster Session 35

Sunday, 13 March
12:15 - 13:45

Location: Room 14b (ICM, Level 1)
Chairs: A. Bossi, Villejuif (FR)
A.S. Merseburger, Lübeck (DE)
R. Sood, New Delhi (IN)

Aims and objectives of this presentation
PSA recurrence after curative treatments is a common problem. During this session we will discuss the patient profile in this situation and 2 adjuvant or salvage modalities with either radiation or PSMA radio guided surgery.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (+) are 3 minutes in length, followed by 3 minutes for discussion.

*430 Patterns of clinical recurrence and predictors of systemic progression of prostate cancer patients with PSA persistence after radical prostatectomy

By: Gandaglia G.¹, Fossati N.², Dell'Oglio P.³, Damiano R.³, Bianchi M.², Picozzi M.², Farina E.², Cucchiara V.², Bertini R.², Dehò F.², Montorsi F.³, Briganti A.³

Institutes: IRCCS Ospedale San Raffaele; Uri, Dept. of Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Oncology and Urology, Milan, Italy, ³Magna Graecia University of Catanzaro, Dept. of Urology, Catanzaro, Italy

*431 External validation of a model predicting survival of men with recurrent prostate cancer after radical prostatectomy

By: Dell'Oglio P.¹, Suardi N.¹, Boorjian S.², Fossati N.¹, Gandaglia G.¹, Tian Z.³, Moschini M.¹, Capitanio U.¹, Karakiewicz P.³, Montorsi F.¹, Karnes J.², Briganti A.¹

Institutes: IRCCS Ospedale San Raffaele, Dept. of Oncology and Urology, Milan, Italy, ²Mayo Clinic, Dept. of Urology, Rochester, United States of America, ³University of Montreal Health Center, Dept. of Cancer Prognostics and Health Outcomes, Montreal, Canada

*432 A novel model to estimate a patient's individual risk of biochemical recurrence after radical prostatectomy

By: Røder M.A.¹, Berg K.D.¹, Thomsen F.B.¹, Kurbegovic S.¹, Rytggaard H.C.², Gruschy L.¹, Brasso K.¹, Gerds T.A.², Iversen P.¹

Institutes: Rigshospitalet, University of Copenhagen, Copenhagen Prostate Cancer Center, Department of Urology, Copenhagen, Denmark, ²University of Copenhagen, Dept. of Biostatistics, Copenhagen, Denmark

*433 Long-term oncological outcomes of salvage radical prostatectomy for radio-recurrent/persistent prostate cancer after radiation therapy

By: Vilaseca Cabo A.¹, Nguyen D.¹, Tin A.², Corradi R.¹, Martin-Malburet A.¹, Sandhu J.¹, Leddy L.¹, Sjoberg D.², Eastham J.¹, Scardino P.¹, Touijer K.¹

Institutes: Memorial Sloan-Kettering Cancer Center, Dept. of Urology, New York, United States of America, ²Memorial Sloan-Kettering Cancer Center, Dept. of Epidemiology and Biostatistics, New York, United States of America

*434 Early or delayed radiotherapy in high risk prostate cancer patients treated with radical prostatectomy? Long term results of a multicenter prospective study

By: Maurizi F.¹, Antognoni P.², Bonetta A.³, Bonetto E.M.⁴, Bortolus R.⁵, Colombo A.⁶, Frezza G.⁷, Gabriele P.⁸, Giacobazzi P.⁹, Marcenaro M.¹⁰, Mattana F.¹¹, Moro G.¹², Rocchi M.B.L.¹³, Signor M.¹⁴
**Efficacy of early and delayed radiation in a prostatectomy cohort adjusted for genomic and clinical risk**


**Institutes:** Johns Hopkins Hospital, James Buchanan Brady Urological Institute, Baltimore, United States of America; Sidney Kimmel Medical College at Thomas Jefferson University, Dept. of Radiation Oncology, Philadelphia, United States of America; GenomeDX Biosciences, Dept. of Biostatistics, Vancouver, Canada; GenomeDX Biosciences, Dept. of Research and Development, Vancouver, Canada; Emmes Canada, Dept. of Biostatistics, Burnaby, Canada; Johns Hopkins Hospital, Dept. of Radiation Oncology, Baltimore, United States of America; Sidney Kimmel Medical College at Thomas Jefferson University, Dept. of Urology, Epidemiology, Oncology, Environmental Health, Philadelphia, United States of America; Sidney Kimmel Medical College at Thomas Jefferson University, Dept. of Urology, Philadelphia, United States of America; Henry Ford Hospital, Dept. of Vattikuti Urology Institute, Detroit, United States of America; University of Michigan, Dept. of Radiation Oncology, Ann Arbor, United States of America; Cedars-Sinai Medical Center, Dept. of Surgery, Division of Urology, Los Angeles, United States of America; Mayo Clinic, Dept. of Urology, Rochester, United States of America.

**The time elapsed between radical prostatectomy and postoperative radiotherapy has a significant impact on the subsequent recovery of erectile function**


**Institutes:** Ircs Ospedale San Raffaele; Uiri, Dept. of Urology, Milan, Italy; Ircs Ospedale San Raffaele, Dept. of Oncology and Urology, Milan, Italy; Magna Gracia University of Catanzaro, Dept. of Urology, Catanzaro, Italy; University of Montreal Health Center, Dept. of Urology, Montreal, Canada; University Federico II, Dept. of Urology, Naples, Italy; Ircs Ospedale San Raffaele, Dept. of Radiotherapy, Milan, Italy.

**Detrimental role of pre-prostatectomy neoadjuvant androgen deprivation in node-negative patients treated with adjuvant RT**

By: Cozzarini C., Noris Chiorda B., Deantonio C., Briganti A., Fiorino C., Gandaglia G., Fossati N., Freschi M., Sini C., Montironi R., Montorsi F., Di Muzio N.

**Institutes:** San Raffaele Scientific Institute, Department of Radiotherapy, Milan, Italy; San Raffaele Scientific Institute, Department of Urology, Milan, Italy; San Raffaele Scientific Institute, Department of Medical Physics, Milan, Italy; San Raffaele Scientific Institute, Department of Pathology, Milan, Italy; Polytechnic University of The Marche Region, School of Medicine, AOU Ospedali Riuniti, Department of Pathology, Ancona, Italy.

**PSMA-radioguided surgery for recurrent prostate cancer – mid-term follow-up and novel developments**


**Institutes:** Technical University of Munich, Dept. of Urology, Munich, Germany; Technical University of Munich, Dept. of Pharmaceutical Radiochemistry, Munich, Germany; Technical University of Munich, Dept. of Radiotherapy, Turin, Italy.
When is tumour volume an exclusion criteria for focal therapy? Results from a radical prostatectomy series
Institutes: IRCCS Ospedale San Raffaele, Division of Oncology/Unit of Urology; URI, Milan, Italy

Expression of steroid hormone receptors in residual cancer and stromal cells after neoadjuvant chemohormonal therapy with docetaxal for high-risk localized prostate cancer
By: Narita N.¹, Nara T.¹, Huang M.¹, Numakura K.¹, Tsuruta H.¹, Maeno A.¹, Saito M.¹, Inoue T.¹, Nanjo H.³, Satoh S.², Habuchi T.¹
Institutes: ¹Akita University School of Medicine, Dept. of Urology, Akita, Japan, ²Akita University Hospital, Enter For Kidney Disease and Transplantation, Akita, Japan, ³Akita University Hospital, Dept. of Pathology, Akita, Japan

Neutrophil-to-lymphocyte ratio is associated with survival after radical prostatectomy in prostate cancer
By: Jang W.S.¹, Kang Y.J.¹, Han J.H.¹, Lee J.Y.¹, Cho K.S.¹, Ham W.S.¹, Oh C.K.⁴, Kim Y.S.², Lee J.S.³, Cho I.R.³, Choi Y.D.¹
Institutes: ¹Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea, ²National Health Insurance Corporation Ilsan Hospital, Dept. of Urology, Goyang, South Korea, ³Cheil General Hospital & Women's Healthcare Center, Dept. of Urology, Seoul, South Korea, ⁴Inje University College of Medicine, Dept. of Urology, Gimhae, South Korea

Summary and context
A.S. Merseburger, Lübeck (DE)